Structure Therapeutics Inc. (GPCR) Current Ratio
- Current ratio · latest quarter: Value 20.75×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 20.75× | Current assets / current liabilities. $1.37B ÷ $66.11M ≈ 20.75× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.37B USD | Assets, Current |
| Current obligations | 66.11M USD | Liabilities, Current |
| Cash and equivalents | 272.64M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 11.13M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.37B | $66.11M | $272.64M | (m) | (m) | (m) | $11.13M | (m) | 20.75× |
| 2026-03-31 | $1.49B | $56.98M | $316.17M | (m) | (m) | (m) | $7.82M | (m) | 26.16× |
| 2025-12-31 | $1.57B | $63.28M | $799.62M | (m) | (m) | (m) | $13.86M | (m) | 24.81× |
| 2025-09-30 | $814.02M | $57.53M | $102.91M | (m) | (m) | (m) | $17.80M | (m) | 14.15× |
| 2025-06-30 | $799.30M | $39.03M | $147.02M | (m) | (m) | (m) | $8.99M | (m) | 20.48× |
| 2025-03-31 | $849.62M | $36.49M | $152.12M | (m) | (m) | (m) | $8.71M | (m) | 23.29× |
| 2024-12-31 | $891.21M | $36.02M | $169.51M | (m) | (m) | (m) | $8.02M | (m) | 24.74× |
| 2024-09-30 | $923.65M | $33.43M | $172.13M | (m) | (m) | (m) | $8.45M | (m) | 27.63× |
| 2024-06-30 | $937.62M | $22.66M | $381.63M | (m) | (m) | (m) | $2.21M | (m) | 41.38× |
| 2024-03-31 | $449.36M | $23.59M | $97.83M | (m) | (m) | (m) | $6.54M | (m) | 19.05× |
| 2023-12-31 | $473.61M | $24.74M | $129.79M | (m) | (m) | (m) | $4.74M | (m) | 19.14× |
| 2023-09-30 | $209.96M | $20.09M | $50.64M | (m) | (m) | (m) | $3.32M | (m) | 10.45× |
| 2023-06-30 | $228.22M | $15.01M | $40.59M | (m) | (m) | (m) | $5.70M | (m) | 15.20× |
| 2023-03-31 | $246.16M | $11.00M | $126.49M | (m) | (m) | (m) | $4.95M | (m) | 22.37× |
| 2022-12-31 | $93.09M | $13.01M | $26.09M | (m) | (m) | (m) | $6.01M | (m) | 7.16× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |